QY Research > レポート一覧 > 薬品及びサプリメント > 糖尿病治療薬ビスフォスフォネート世界市場の発展状況と動向 2024-2030

糖尿病治療薬ビスフォスフォネート世界市場の発展状況と動向 2024-2030

英文タイトル: Global Antidiabetic Biguanides Market Insights, Forecast to 2030

糖尿病治療薬ビスフォスフォネート世界市場の発展状況と動向 2024-2030
  • レポートID:271236
  • 発表時期:2024-04-25
  • 訪問回数:261
  • ページ数:105
  • レポート形式:PDF
  • レポート言語:英語、日本語
  • グラフ数:133
  • レポートカテゴリ: 薬品及びサプリメント

販売価格(消費税別)

販売価格(消費税別)

  •  
  • 個人版

    詳細
  • マルチユーザー版

    詳細
  • 企業版

    詳細

価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=161円。
※米ドル表示価格+10%消費税。

英語版
日本語版
英語と日本語版

価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=161円。
※米ドル表示価格+10%消費税。

shenQingYangBen

お見積

shenQingYangBen

サンプルお申込み

※ご注文方法:お問い合わせフォームまたはメールにてご連絡ください。
支払方法:「銀行振込」の場合, 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期:原則として、受注後2~4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8~10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

biaoTi

概要

本報告書は、糖尿病治療薬ビスフォスフォネートの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に糖尿病治療薬ビスフォスフォネート市場を分類しています。

本レポートでは世界の糖尿病治療薬ビスフォスフォネート市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は:Pfizer、AstraZeneca、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb

レポートは糖尿病治療薬ビスフォスフォネートの主要生産者を調査し、主要地域や国の消費状況も提供します。糖尿病治療薬ビスフォスフォネートの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。

タイプ別市場セグメント:
Metformin IR
Metformin SR

用途別の市場セグメント:
Hospitals
Clinics
Other

レポートの詳細内容
本レポートは、世界の糖尿病治療薬ビスフォスフォネート市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて糖尿病治療薬ビスフォスフォネート市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。

一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別(地域レベル、国レベル)の糖尿病治療薬ビスフォスフォネート生産量、成長率、市場シェアを調査している。

二. 消費面では、糖尿病治療薬ビスフォスフォネートの売上高を地域別(地域レベル・国レベル)、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーの糖尿病治療薬ビスフォスフォネート売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の糖尿病治療薬ビスフォスフォネート市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本糖尿病治療薬ビスフォスフォネートのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要

1章:糖尿病治療薬ビスフォスフォネートのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー(タイプ別およびアプリケーション別など)を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。(20192030
2章: 糖尿病治療薬ビスフォスフォネートの世界と主要生産者(地域/国)の生産/アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。(20192030
3章:世界、地域、国レベルにおける糖尿病治療薬ビスフォスフォネートの売上(消費)、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。(20192030
4糖尿病治療薬ビスフォスフォネートメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。(20192024
5章:糖尿病治療薬ビスフォスフォネートの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。(20192030
6章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。(20192030
7章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の売上高、収益。(20192030
8章:ヨーロッパ:タイプ別、用途別、国別、セグメント別の売上高と収益。(20192030
9章:中国:タイプ別、アプリケーション別、セグメント別の売上高、収益。(20192030
10章:アジア(中国を除く):タイプ別、用途別、地域別、セグメント別の売上高、収益。(20192030
11章:中東、アフリカ、中南米:タイプ別、用途別、国別、セグメント別の売上高、収益。(20192030
12章:糖尿病治療薬ビスフォスフォネートの主要メーカーの概要を提供し、製品の説明と仕様、糖尿病治療薬ビスフォスフォネートの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。(20192024
13章:産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
14章:糖尿病治療薬ビスフォスフォネートの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
15章:レポートの要点と結論。

biaoTi

概要

The global Antidiabetic Biguanides market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Antidiabetic Biguanides, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Antidiabetic Biguanides, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Antidiabetic Biguanides, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antidiabetic Biguanides sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Antidiabetic Biguanides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Antidiabetic Biguanides sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, AstraZeneca, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk and Servier Laboratories, etc.

Market Segmentation
By Company
    Pfizer
    AstraZeneca
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb

Segment by Type
    Metformin IR
    Metformin SR

Segment by Application
    Hospitals
    Clinics
    Other

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Antidiabetic Biguanides in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antidiabetic Biguanides sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
biaoTi

総目録

1 Study Coverage
1.1 Antidiabetic Biguanides Product Introduction
1.2 Market by Type
1.2.1 Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Metformin IR
1.2.3 Metformin SR
1.3 Market by Application
1.3.1 Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Executive Summary
2.1 Global Antidiabetic Biguanides Sales Estimates and Forecasts 2019-2030
2.2 Global Antidiabetic Biguanides Revenue by Region
2.2.1 Global Antidiabetic Biguanides Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Antidiabetic Biguanides Revenue by Region (2019-2024)
2.2.3 Global Antidiabetic Biguanides Revenue by Region (2025-2030)
2.2.4 Global Antidiabetic Biguanides Revenue Market Share by Region (2019-2030)
2.3 Global Antidiabetic Biguanides Sales Estimates and Forecasts 2019-2030
2.4 Global Antidiabetic Biguanides Sales by Region
2.4.1 Global Antidiabetic Biguanides Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Antidiabetic Biguanides Sales by Region (2019-2024)
2.4.3 Global Antidiabetic Biguanides Sales by Region (2025-2030)
2.4.4 Global Antidiabetic Biguanides Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America

3 Competition by Manufactures
3.1 Global Antidiabetic Biguanides Sales by Manufacturers
3.1.1 Global Antidiabetic Biguanides Sales by Manufacturers (2019-2024)
3.1.2 Global Antidiabetic Biguanides Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antidiabetic Biguanides in 2023
3.2 Global Antidiabetic Biguanides Revenue by Manufacturers
3.2.1 Global Antidiabetic Biguanides Revenue by Manufacturers (2019-2024)
3.2.2 Global Antidiabetic Biguanides Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antidiabetic Biguanides Revenue in 2023
3.3 Global Key Players of Antidiabetic Biguanides, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Antidiabetic Biguanides Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antidiabetic Biguanides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antidiabetic Biguanides, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antidiabetic Biguanides, Product Offered and Application
3.8 Global Key Manufacturers of Antidiabetic Biguanides, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Antidiabetic Biguanides Sales by Type
4.1.1 Global Antidiabetic Biguanides Historical Sales by Type (2019-2024)
4.1.2 Global Antidiabetic Biguanides Forecasted Sales by Type (2025-2030)
4.1.3 Global Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
4.2 Global Antidiabetic Biguanides Revenue by Type
4.2.1 Global Antidiabetic Biguanides Historical Revenue by Type (2019-2024)
4.2.2 Global Antidiabetic Biguanides Forecasted Revenue by Type (2025-2030)
4.2.3 Global Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
4.3 Global Antidiabetic Biguanides Price by Type
4.3.1 Global Antidiabetic Biguanides Price by Type (2019-2024)
4.3.2 Global Antidiabetic Biguanides Price Forecast by Type (2025-2030)

5 Market Size by Application
5.1 Global Antidiabetic Biguanides Sales by Application
5.1.1 Global Antidiabetic Biguanides Historical Sales by Application (2019-2024)
5.1.2 Global Antidiabetic Biguanides Forecasted Sales by Application (2025-2030)
5.1.3 Global Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
5.2 Global Antidiabetic Biguanides Revenue by Application
5.2.1 Global Antidiabetic Biguanides Historical Revenue by Application (2019-2024)
5.2.2 Global Antidiabetic Biguanides Forecasted Revenue by Application (2025-2030)
5.2.3 Global Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
5.3 Global Antidiabetic Biguanides Price by Application
5.3.1 Global Antidiabetic Biguanides Price by Application (2019-2024)
5.3.2 Global Antidiabetic Biguanides Price Forecast by Application (2025-2030)

6 US & Canada
6.1 US & Canada Antidiabetic Biguanides Market Size by Type
6.1.1 US & Canada Antidiabetic Biguanides Sales by Type (2019-2030)
6.1.2 US & Canada Antidiabetic Biguanides Revenue by Type (2019-2030)
6.2 US & Canada Antidiabetic Biguanides Market Size by Application
6.2.1 US & Canada Antidiabetic Biguanides Sales by Application (2019-2030)
6.2.2 US & Canada Antidiabetic Biguanides Revenue by Application (2019-2030)
6.3 US & Canada Antidiabetic Biguanides Market Size by Country
6.3.1 US & Canada Antidiabetic Biguanides Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Antidiabetic Biguanides Sales by Country (2019-2030)
6.3.3 US & Canada Antidiabetic Biguanides Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada

7 Europe
7.1 Europe Antidiabetic Biguanides Market Size by Type
7.1.1 Europe Antidiabetic Biguanides Sales by Type (2019-2030)
7.1.2 Europe Antidiabetic Biguanides Revenue by Type (2019-2030)
7.2 Europe Antidiabetic Biguanides Market Size by Application
7.2.1 Europe Antidiabetic Biguanides Sales by Application (2019-2030)
7.2.2 Europe Antidiabetic Biguanides Revenue by Application (2019-2030)
7.3 Europe Antidiabetic Biguanides Market Size by Country
7.3.1 Europe Antidiabetic Biguanides Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Antidiabetic Biguanides Sales by Country (2019-2030)
7.3.3 Europe Antidiabetic Biguanides Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia

8 China
8.1 China Antidiabetic Biguanides Market Size
8.1.1 China Antidiabetic Biguanides Sales (2019-2030)
8.1.2 China Antidiabetic Biguanides Revenue (2019-2030)
8.2 China Antidiabetic Biguanides Market Size by Application
8.2.1 China Antidiabetic Biguanides Sales by Application (2019-2030)
8.2.2 China Antidiabetic Biguanides Revenue by Application (2019-2030)

9 Asia (excluding China)
9.1 Asia Antidiabetic Biguanides Market Size by Type
9.1.1 Asia Antidiabetic Biguanides Sales by Type (2019-2030)
9.1.2 Asia Antidiabetic Biguanides Revenue by Type (2019-2030)
9.2 Asia Antidiabetic Biguanides Market Size by Application
9.2.1 Asia Antidiabetic Biguanides Sales by Application (2019-2030)
9.2.2 Asia Antidiabetic Biguanides Revenue by Application (2019-2030)
9.3 Asia Antidiabetic Biguanides Sales by Region
9.3.1 Asia Antidiabetic Biguanides Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Antidiabetic Biguanides Revenue by Region (2019-2030)
9.3.3 Asia Antidiabetic Biguanides Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India

10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antidiabetic Biguanides Market Size by Type
10.1.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Antidiabetic Biguanides Market Size by Application
10.2.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Country
10.3.1 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Pfizer Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 AstraZeneca Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 GlaxoSmithKline Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKline Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Information
11.4.2 Merck & Co Overview
11.4.3 Merck & Co Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Merck & Co Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck & Co Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Overview
11.5.3 Eli Lilly Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Eli Lilly Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eli Lilly Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Overview
11.6.3 Sanofi Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Sanofi Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sanofi Recent Developments
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Company Information
11.7.2 Takeda Pharmaceuticals Overview
11.7.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Takeda Pharmaceuticals Recent Developments
11.8 Novo Nordisk
11.8.1 Novo Nordisk Company Information
11.8.2 Novo Nordisk Overview
11.8.3 Novo Nordisk Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Novo Nordisk Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novo Nordisk Recent Developments
11.9 Servier Laboratories
11.9.1 Servier Laboratories Company Information
11.9.2 Servier Laboratories Overview
11.9.3 Servier Laboratories Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Servier Laboratories Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Servier Laboratories Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Overview
11.10.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Boehringer Ingelheim Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Boehringer Ingelheim Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Information
11.11.2 Bristol-Myers Squibb Overview
11.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Bristol-Myers Squibb Recent Developments

12 Industry Chain and Sales Channels Analysis
12.1 Antidiabetic Biguanides Industry Chain Analysis
12.2 Antidiabetic Biguanides Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antidiabetic Biguanides Production Mode & Process
12.4 Antidiabetic Biguanides Sales and Marketing
12.4.1 Antidiabetic Biguanides Sales Channels
12.4.2 Antidiabetic Biguanides Distributors
12.5 Antidiabetic Biguanides Customers

13 Market Dynamics
13.1 Antidiabetic Biguanides Industry Trends
13.2 Antidiabetic Biguanides Market Drivers
13.3 Antidiabetic Biguanides Market Challenges
13.4 Antidiabetic Biguanides Market Restraints

14 Key Findings in The Global Antidiabetic Biguanides Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

biaoTi

表と図のリスト

List of Tables
    Table 1. Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of Metformin IR
    Table 3. Major Manufacturers of Metformin SR
    Table 4. Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 5. Global Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Antidiabetic Biguanides Revenue by Region (2019-2024) & (US$ Million)
    Table 7. Global Antidiabetic Biguanides Revenue by Region (2025-2030) & (US$ Million)
    Table 8. Global Antidiabetic Biguanides Revenue Market Share by Region (2019-2024)
    Table 9. Global Antidiabetic Biguanides Revenue Market Share by Region (2025-2030)
    Table 10. Global Antidiabetic Biguanides Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 11. Global Antidiabetic Biguanides Sales by Region (2019-2024) & (K Pcs)
    Table 12. Global Antidiabetic Biguanides Sales by Region (2025-2030) & (K Pcs)
    Table 13. Global Antidiabetic Biguanides Sales Market Share by Region (2019-2024)
    Table 14. Global Antidiabetic Biguanides Sales Market Share by Region (2025-2030)
    Table 15. Global Antidiabetic Biguanides Sales by Manufacturers (2019-2024) & (K Pcs)
    Table 16. Global Antidiabetic Biguanides Sales Share by Manufacturers (2019-2024)
    Table 17. Global Antidiabetic Biguanides Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 18. Global Antidiabetic Biguanides Revenue Share by Manufacturers (2019-2024)
    Table 19. Global Key Players of Antidiabetic Biguanides, Industry Ranking, 2022 VS 2023 VS 2024
    Table 20. Antidiabetic Biguanides Price by Manufacturers 2019-2024 (USD/Pcs)
    Table 21. Global Antidiabetic Biguanides Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Antidiabetic Biguanides by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic Biguanides as of 2023)
    Table 23. Global Key Manufacturers of Antidiabetic Biguanides, Manufacturing Base Distribution and Headquarters
    Table 24. Global Key Manufacturers of Antidiabetic Biguanides, Product Offered and Application
    Table 25. Global Key Manufacturers of Antidiabetic Biguanides, Date of Enter into This Industry
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 28. Global Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 29. Global Antidiabetic Biguanides Sales Share by Type (2019-2024)
    Table 30. Global Antidiabetic Biguanides Sales Share by Type (2025-2030)
    Table 31. Global Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 32. Global Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 33. Global Antidiabetic Biguanides Revenue Share by Type (2019-2024)
    Table 34. Global Antidiabetic Biguanides Revenue Share by Type (2025-2030)
    Table 35. Antidiabetic Biguanides Price by Type (2019-2024) & (USD/Pcs)
    Table 36. Global Antidiabetic Biguanides Price Forecast by Type (2025-2030) & (USD/Pcs)
    Table 37. Global Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 38. Global Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 39. Global Antidiabetic Biguanides Sales Share by Application (2019-2024)
    Table 40. Global Antidiabetic Biguanides Sales Share by Application (2025-2030)
    Table 41. Global Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 42. Global Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 43. Global Antidiabetic Biguanides Revenue Share by Application (2019-2024)
    Table 44. Global Antidiabetic Biguanides Revenue Share by Application (2025-2030)
    Table 45. Antidiabetic Biguanides Price by Application (2019-2024) & (USD/Pcs)
    Table 46. Global Antidiabetic Biguanides Price Forecast by Application (2025-2030) & (USD/Pcs)
    Table 47. US & Canada Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 48. US & Canada Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 49. US & Canada Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 50. US & Canada Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 51. US & Canada Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 52. US & Canada Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 53. US & Canada Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 54. US & Canada Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 55. US & Canada Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 56. US & Canada Antidiabetic Biguanides Revenue by Country (2019-2024) & (US$ Million)
    Table 57. US & Canada Antidiabetic Biguanides Revenue by Country (2025-2030) & (US$ Million)
    Table 58. US & Canada Antidiabetic Biguanides Sales by Country (2019-2024) & (K Pcs)
    Table 59. US & Canada Antidiabetic Biguanides Sales by Country (2025-2030) & (K Pcs)
    Table 60. Europe Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 61. Europe Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 62. Europe Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 63. Europe Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 64. Europe Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 65. Europe Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 66. Europe Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 67. Europe Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 68. Europe Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 69. Europe Antidiabetic Biguanides Revenue by Country (2019-2024) & (US$ Million)
    Table 70. Europe Antidiabetic Biguanides Revenue by Country (2025-2030) & (US$ Million)
    Table 71. Europe Antidiabetic Biguanides Sales by Country (2019-2024) & (K Pcs)
    Table 72. Europe Antidiabetic Biguanides Sales by Country (2025-2030) & (K Pcs)
    Table 73. China Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 74. China Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 75. China Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 76. China Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 77. China Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 78. China Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 79. China Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 80. China Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 81. Asia Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 82. Asia Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 83. Asia Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 84. Asia Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 85. Asia Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 86. Asia Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 87. Asia Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 88. Asia Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 89. Asia Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 90. Asia Antidiabetic Biguanides Revenue by Region (2019-2024) & (US$ Million)
    Table 91. Asia Antidiabetic Biguanides Revenue by Region (2025-2030) & (US$ Million)
    Table 92. Asia Antidiabetic Biguanides Sales by Region (2019-2024) & (K Pcs)
    Table 93. Asia Antidiabetic Biguanides Sales by Region (2025-2030) & (K Pcs)
    Table 94. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Type (2019-2024) & (K Pcs)
    Table 95. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Type (2025-2030) & (K Pcs)
    Table 96. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2019-2024) & (US$ Million)
    Table 97. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2025-2030) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Application (2019-2024) & (K Pcs)
    Table 99. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Application (2025-2030) & (K Pcs)
    Table 100. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2019-2024) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2025-2030) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 103. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2019-2024) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2025-2030) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Country (2019-2024) & (K Pcs)
    Table 106. Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Country (2025-2030) & (K Pcs)
    Table 107. Pfizer Company Information
    Table 108. Pfizer Description and Major Businesses
    Table 109. Pfizer Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 110. Pfizer Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Pfizer Recent Developments
    Table 112. AstraZeneca Company Information
    Table 113. AstraZeneca Description and Major Businesses
    Table 114. AstraZeneca Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 115. AstraZeneca Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. AstraZeneca Recent Developments
    Table 117. GlaxoSmithKline Company Information
    Table 118. GlaxoSmithKline Description and Major Businesses
    Table 119. GlaxoSmithKline Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 120. GlaxoSmithKline Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. GlaxoSmithKline Recent Developments
    Table 122. Merck & Co Company Information
    Table 123. Merck & Co Description and Major Businesses
    Table 124. Merck & Co Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 125. Merck & Co Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Merck & Co Recent Developments
    Table 127. Eli Lilly Company Information
    Table 128. Eli Lilly Description and Major Businesses
    Table 129. Eli Lilly Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 130. Eli Lilly Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Eli Lilly Recent Developments
    Table 132. Sanofi Company Information
    Table 133. Sanofi Description and Major Businesses
    Table 134. Sanofi Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 135. Sanofi Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Sanofi Recent Developments
    Table 137. Takeda Pharmaceuticals Company Information
    Table 138. Takeda Pharmaceuticals Description and Major Businesses
    Table 139. Takeda Pharmaceuticals Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 140. Takeda Pharmaceuticals Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Takeda Pharmaceuticals Recent Developments
    Table 142. Novo Nordisk Company Information
    Table 143. Novo Nordisk Description and Major Businesses
    Table 144. Novo Nordisk Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 145. Novo Nordisk Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Novo Nordisk Recent Developments
    Table 147. Servier Laboratories Company Information
    Table 148. Servier Laboratories Description and Major Businesses
    Table 149. Servier Laboratories Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 150. Servier Laboratories Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. Servier Laboratories Recent Developments
    Table 152. Boehringer Ingelheim Company Information
    Table 153. Boehringer Ingelheim Description and Major Businesses
    Table 154. Boehringer Ingelheim Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 155. Boehringer Ingelheim Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Boehringer Ingelheim Recent Developments
    Table 157. Bristol-Myers Squibb Company Information
    Table 158. Bristol-Myers Squibb Description and Major Businesses
    Table 159. Bristol-Myers Squibb Antidiabetic Biguanides Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 160. Bristol-Myers Squibb Antidiabetic Biguanides Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. Bristol-Myers Squibb Recent Developments
    Table 162. Key Raw Materials Lists
    Table 163. Raw Materials Key Suppliers Lists
    Table 164. Antidiabetic Biguanides Distributors List
    Table 165. Antidiabetic Biguanides Customers List
    Table 166. Antidiabetic Biguanides Market Trends
    Table 167. Antidiabetic Biguanides Market Drivers
    Table 168. Antidiabetic Biguanides Market Challenges
    Table 169. Antidiabetic Biguanides Market Restraints
    Table 170. Research Programs/Design for This Report
    Table 171. Key Data Information from Secondary Sources
    Table 172. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antidiabetic Biguanides Product Picture
    Figure 2. Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Antidiabetic Biguanides Market Share by Type in 2023 & 2030
    Figure 4. Metformin IR Product Picture
    Figure 5. Metformin SR Product Picture
    Figure 6. Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Antidiabetic Biguanides Market Share by Application in 2023 & 2030
    Figure 8. Hospitals
    Figure 9. Clinics
    Figure 10. Other
    Figure 11. Antidiabetic Biguanides Report Years Considered
    Figure 12. Global Antidiabetic Biguanides Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Antidiabetic Biguanides Revenue 2019-2030 (US$ Million)
    Figure 14. Global Antidiabetic Biguanides Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 15. Global Antidiabetic Biguanides Revenue Market Share by Region (2019-2030)
    Figure 16. Global Antidiabetic Biguanides Sales 2019-2030 ((K Pcs)
    Figure 17. Global Antidiabetic Biguanides Sales Market Share by Region (2019-2030)
    Figure 18. US & Canada Antidiabetic Biguanides Sales YoY (2019-2030) & (K Pcs)
    Figure 19. US & Canada Antidiabetic Biguanides Revenue YoY (2019-2030) & (US$ Million)
    Figure 20. Europe Antidiabetic Biguanides Sales YoY (2019-2030) & (K Pcs)
    Figure 21. Europe Antidiabetic Biguanides Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. China Antidiabetic Biguanides Sales YoY (2019-2030) & (K Pcs)
    Figure 23. China Antidiabetic Biguanides Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. Asia (excluding China) Antidiabetic Biguanides Sales YoY (2019-2030) & (K Pcs)
    Figure 25. Asia (excluding China) Antidiabetic Biguanides Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Middle East, Africa and Latin America Antidiabetic Biguanides Sales YoY (2019-2030) & (K Pcs)
    Figure 27. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. The Antidiabetic Biguanides Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 29. The Top 5 and 10 Largest Manufacturers of Antidiabetic Biguanides in the World: Market Share by Antidiabetic Biguanides Revenue in 2023
    Figure 30. Global Antidiabetic Biguanides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 31. Global Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 32. Global Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 33. Global Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 34. Global Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 35. US & Canada Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 36. US & Canada Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 37. US & Canada Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 38. US & Canada Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 39. US & Canada Antidiabetic Biguanides Revenue Share by Country (2019-2030)
    Figure 40. US & Canada Antidiabetic Biguanides Sales Share by Country (2019-2030)
    Figure 41. U.S. Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 42. Canada Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 43. Europe Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 44. Europe Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 45. Europe Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 46. Europe Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 47. Europe Antidiabetic Biguanides Revenue Share by Country (2019-2030)
    Figure 48. Europe Antidiabetic Biguanides Sales Share by Country (2019-2030)
    Figure 49. Germany Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 50. France Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 51. U.K. Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 52. Italy Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 53. Russia Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 54. China Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 55. China Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 56. China Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 57. China Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 58. Asia Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 59. Asia Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 60. Asia Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 61. Asia Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 62. Asia Antidiabetic Biguanides Revenue Share by Region (2019-2030)
    Figure 63. Asia Antidiabetic Biguanides Sales Share by Region (2019-2030)
    Figure 64. Japan Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 65. South Korea Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 66. China Taiwan Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 67. Southeast Asia Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 68. India Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 69. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
    Figure 70. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
    Figure 71. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
    Figure 72. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
    Figure 73. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Share by Country (2019-2030)
    Figure 74. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Share by Country (2019-2030)
    Figure 75. Brazil Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 76. Mexico Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 77. Turkey Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 78. Israel Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 79. GCC Countries Antidiabetic Biguanides Revenue (2019-2030) & (US$ Million)
    Figure 80. Antidiabetic Biguanides Value Chain
    Figure 81. Antidiabetic Biguanides Production Process
    Figure 82. Channels of Distribution
    Figure 83. Distributors Profiles
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed
当社から購入のメリット
サンプル提供

01. サンプル提供

ご購入前にサンプル(英語、日本語)が提供可能。

カスタマイズサービス

02. カスタマイズサービス

レポートの一部をご購入可能;基本バージョンに加え、ご要望に応じたカスタム委託調査も提供可能。

プロフェッショナルな日本語翻訳

03. プロフェッショナルな日本語翻訳

AI翻訳ではなく、プロフェッショナルな日本語翻訳をご提供。納期:英語は2-4営業日以内、日本語は8-10営業日以内。

多言語コミュニケーション

04. 多言語コミュニケーション

日本語、英語、中国語、ヒンディー語、ドイツ語、韓国語、フランス語の7ヶ国語でコミュニケーションサービスをご提供。

 お支払方法

05. お支払方法

銀行振込(納品後、ご請求書送付)。

アフターサービス

06. アフターサービス

ご購入後、ご質問があれば、3ヵ月以内に無料でアナリストと直接的に連絡できる。

ご注文方法

請求書払いの場合:

  • yuan01

    レポート選択

  • yuan01

    見積もり依頼

  • yuan01

    メールでのご注文

  • yuan01

    入手(英語版は2〜4営業日、日本語版は8〜10営業日)

  • yuan01

    決済(後払い)

クレジットカード決済の場合:

  • yuan01

    レポート選択

  • yuan01

    ウェブサイトでのご注文

  • yuan01

    決済

  • yuan01

    入手(英語版は2〜4営業日、日本語版は8〜10営業日)